Related Experiment Video

Updated: Aug 7, 2026

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells
06:29

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells

Published on: July 30, 2020

PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity

Chiara Soncini1, Patrizia Carpinelli, Laura Gianellini

  • 1Nerviano Medical Sciences S.r.l.-Oncology, Milan, Italy.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|July 5, 2006
PubMed
Abstract

Insights

A novel Aurora kinase inhibitor, PHA-680632, effectively inhibits cancer cell growth and tumor progression in preclinical models. Its mechanism involves Aurora kinase inhibition, with histone H3 phosphorylation serving as a reliable biomarker for therapeutic activity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Aurora kinases are crucial regulators of mitosis, essential for accurate chromosome segregation and cell division.
  • Dysregulation of Aurora kinases is implicated in various cancers, making them attractive therapeutic targets.

Purpose of the Study:

  • To evaluate the preclinical profile of PHA-680632, a novel, selective Aurora kinase inhibitor.
  • To assess its potential as an anticancer therapeutic agent.

Main Methods:

  • Biochemical kinase assays and proliferation assays across diverse cancer cell lines.
  • Mechanism of action studies using cell cycle analysis, Western blotting, and immunohistochemistry.
  • In vivo efficacy evaluation in xenograft and transgenic breast cancer models.

Main Results:

  • PHA-680632 demonstrated broad-spectrum antiproliferative activity against numerous cancer cell lines.
  • Significant tumor growth inhibition was observed in animal models at well-tolerated doses.
  • Inhibition of Aurora B kinase activity, evidenced by decreased histone H3 phosphorylation, was confirmed as the mechanism of action.

Conclusions:

  • PHA-680632 represents a new class of Aurora kinase inhibitors with significant anticancer therapeutic potential.
  • Differential cellular responses suggest potential for a favorable therapeutic window based on cell cycle checkpoint status.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...